Thus, attenuating the inflammatory response by modulating the NLRP3 complex has become a new therapeutic strategy in the context of kidney diseases, especially those related to DM, aiming to reduce disease progression by reducing the inflammatory response mediated by the NLRP3 complex. Here, NLRP3 is linked to diabetes mellitus.